Stockscreener 앱 받기
13.07
0.23%
-0.03
시간 외 거래:
13.07
전일 마감가:
$13.10
열려 있는:
$13.49
하루 거래량:
1.08M
Relative Volume:
0.78
시가총액:
$1.68B
수익:
-
순이익/손실:
$-42.76M
주가수익비율:
-40.74
EPS:
-0.3208
순현금흐름:
$-42.09M
1주 성능:
+12.87%
1개월 성능:
-1.73%
6개월 성능:
+33.10%
1년 성능:
+146.60%
1일 변동 폭
$12.74
$13.59
1주일 범위
$11.27
$13.59
52주 변동 폭
$4.85
$14.39
트레비 테라퓨틱스 Stock (TRVI) Company Profile
명칭
Trevi Therapeutics Inc
전화
203-304-2499
주소
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
13.07 | 1.68B | 0 | -42.76M | -42.09M | -0.3208 |
VRTX
Vertex Pharmaceuticals Inc
|
443.92 | 109.85B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
775.53 | 80.38B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
785.07 | 47.60B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
327.25 | 42.63B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.19 | 33.72B | 5.36B | 287.73M | 924.18M | 2.5229 |
트레비 테라퓨틱스 Stock (TRVI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-13 | 개시 | Leerink Partners | Outperform |
| 2025-08-21 | 개시 | Morgan Stanley | Overweight |
| 2025-07-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-05-28 | 개시 | H.C. Wainwright | Buy |
| 2025-03-10 | 재확인 | Needham | Buy |
| 2025-03-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-08-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-30 | 개시 | Raymond James | Outperform |
| 2024-06-13 | 개시 | Rodman & Renshaw | Buy |
| 2023-04-12 | 개시 | B. Riley Securities | Buy |
| 2022-11-22 | 개시 | SVB Leerink | Outperform |
| 2019-06-03 | 개시 | BMO Capital Markets | Outperform |
| 2019-06-03 | 개시 | Needham | Buy |
| 2019-06-03 | 개시 | SVB Leerink | Outperform |
| 2019-06-03 | 개시 | Stifel | Buy |
모두보기
트레비 테라퓨틱스 주식(TRVI)의 최신 뉴스
Trevi Therapeutics (NASDAQ:TRVI) Trading Up 7.2%Here's What Happened - MarketBeat
Trevi Therapeutics, Inc. (TRVI) stock price, news, quote and history - Yahoo Finance Singapore
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2025 earnings call transcript - MSN
A Look At Trevi Therapeutics (TRVI) Valuation After FDA End Of Phase 2 Milestone For IPF Chronic Cough - Yahoo Finance
TRVI Technical Analysis & Stock Price Forecast - Intellectia AI
Trevi Therapeutics, Inc. (TRVI) Stock Price, News, Quote & History - Yahoo! Finance Canada
Trevi Therapeutics to Participate in Upcoming Events - Sahm
These analysts revise their forecasts on Trevi Therapeutics following Q4 earnings - MSN
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Vanguard (TRVI) amends 13G/A after Jan 12, 2026 realignment - Stock Titan
Trevi Therapeutics (NASDAQ:TRVI) Shares Up 9.4%What's Next? - MarketBeat
Aug Wrap: Will Trevi Therapeutics Inc outperform tech stocks2026 Trading Recap & AI Powered Trade Plan Recommendations - baoquankhu1.vn
TRVI SEC FilingsTrevi Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
TRVI Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Trevi Therapeutics edges higher amid takeover speculation - MSN
Research Analysts Issue Forecasts for TRVI FY2026 Earnings - MarketBeat
Trevi Therapeutics to Participate in Upcoming September Events - GuruFocus
Trading Action: Can Trevi Therapeutics Inc continue delivering strong returnsMarket Risk Summary & Detailed Earnings Play Alerts - baoquankhu1.vn
These Analysts Revise Their Forecasts On Trevi Therapeutics Following Q4 Earnings - Sahm
TRVI: Jones Trading Lowers Price Target While Maintaining Buy Ra - GuruFocus
Trevi Therapeutics (NASDAQ:TRVI) Given New $24.00 Price Target at JonesTrading - MarketBeat
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2025 Earnings Call Transcript - Insider Monkey
Cantor Fitzgerald Sticks to Its Buy Rating for Trevi Therapeutics (TRVI) - The Globe and Mail
What is HC Wainwright's Forecast for TRVI Q1 Earnings? - MarketBeat
Does Trevi Therapeutics (TRVI) have the potential to rally 102.07% as Wall Street analysts expect? - MSN
Trevi Therapeutics Q4 Earnings Call Highlights - MarketBeat
Trevi Therapeutics (TRVI) Q4 Loss Narrows to $0.06/Share vs $0.10 Estimate, 37% Better Than Expected - news.alphastreet.com
Morgan Stanley Lowers Price Target for Trevi Therapeutics (TRVI) to $18.00 | TRVI Stock News - gurufocus.com
Trevi Therapeutics (NASDAQ:TRVI) Given New $18.00 Price Target at Morgan Stanley - MarketBeat
Cantor Fitzgerald reiterates Trevi Therapeutics stock Overweight rating By Investing.com - Investing.com India
Trevi Therapeutics Chronic Cough Programs: FDA End-of-Phase 2 Meeting & Phase III PlansNews and Statistics - IndexBox
Trevi Therapeutics 2025 Annual Report Highlights: Haduvio Development, Clinical Progress, and Competitive Position - Minichart
Trevi Therapeutics plans two pivotal phase III trials for IPF-related chronic cough as FDA alignment achieved - MSN
Trevi Therapeutics (NASDAQ:TRVI) Shares Gap Up After Better-Than-Expected Earnings - MarketBeat
Trevi Therapeutics (TRVI) Earnings Transcript - AOL.com
TRVI: Today's Analyst Rating Maintained at Buy with $19 Target | - gurufocus.com
Needham raises Trevi Therapeutics stock price target on trial plans By Investing.com - Investing.com Canada
Cantor Fitzgerald reiterates Trevi Therapeutics stock Overweight rating - Investing.com
Trevi Therapeutics (NASDAQ:TRVI) Earns Buy Rating from D. Boral Capital - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Price Target Raised to $24.00 - MarketBeat
Trevi Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Nvidia To Rally Around 79%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
트레비 테라퓨틱스 (TRVI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.51%
1.75%
자본화:
|
볼륨(24시간):